Thursday, December 3, 2015

E-Waste Recycling

Please support UE's Lego Robotics team, the BROBOTS, in their effort to reduce the amount of e-waste going to landfills by bringing your old electronics and used ink and toner cartridges to school for recycling.  Donations should be placed in the red bins in the front lobby or parent pick-up area.

The following e-waste will be accepted:  empty ink and toner cartridges, desktop computers, laptops, tablets, eReaders, monitors, printers, copiers, scanners, fax machines, shredders, keyboards, external mouse devices, modems, routers, speakers, mobile phones, MP3 players, iPods, calculators, digital cameras, camcorders, cordless phones, cd/dvd players, gaming consoles, external hard drives and small rechargeable batteries. 

If you are recycling a computer, please complete a drop-off waiver.  Waivers are located in the donation bins. 

Questions:  Please contact Kristin Scali at

Help UES earn A+ Rewards

Please take a few minutes to register or reregister your Giant Card so UES can earn A+ Rewards. Register your card at:

You will need your Giant Card number.  Our school ID# is 23973.

Ask family and friends to register too. 
Registering for A+ Rewards does not affect your Giant gas/turkey points.

Thursday, October 29, 2015

Auvi-Q Recall Due to Potential Inaccurate Dosage Delivery

Note from the Nurse for all parents of students with Life Threatening Allergies:

Sanofi US Issues Voluntary Nationwide Recall of Auvi‑Q® Due to Potential Inaccurate Dosage Delivery

Sanofi US is voluntarily recalling all Auvi‑Q® (epinephrine injection, USP). The recall involves all Auvi‑Q currently on the market and includes both the 0.15 mg and 0.3 mg strengths for hospitals, retailers and consumers. This includes lot number 2299596 through 3037230, which expire March 2016 through December 2016. The products have been found to potentially have inaccurate dosage delivery.

If a patient experiencing a serious allergic reaction (i.e., anaphylaxis) did not receive the intended dose, there could be significant health consequences, including death because anaphylaxis is a potentially life‑threatening condition. As of October 26, 2015, Sanofi has received 26 reports of suspected device malfunctions in the US and Canada. None of these device malfunction reports have been confirmed. In these reports, patients have described symptoms of the underlying hypersensitivity reaction. No fatal outcomes have been reported among these cases.

Auvi‑Q (epinephrine injection, USP) is used to treat life‑threatening allergic reactions (anaphylaxis) in people who are at risk for or have a history of these reactions. Auvi‑Q is packaged with two active devices and one trainer device in a corrugate box. Auvi‑Q was distributed throughout the United States via wholesalers, pharmacies and hospitals. All Auvi‑Q is being recalled.

Sanofi US is notifying its distributors and customers who include doctors, pharmacies, wholesalers and other customers in the supply chain by letter, fax, email and phone calls and is arranging for return and reimbursement of all recalled products.

Customers with questions regarding this recall can go to www.Auvi‑ and call 1‑866‑726‑6340 Monday through Friday 8 a.m. to 8 p.m. ET for information about how to return their Auvi‑Q devices. Customers may also email Sanofi US will provide reimbursement for out of pocket costs incurred for the purchase of new epinephrine auto‑injectors with proof of purchase.

Customers should immediately contact their healthcare provider (HCP) for a prescription for an alternate epinephrine auto‑injector. In the event of a life‑threatening allergic reaction (anaphylaxis), patients should only use their Auvi‑Q device if another epinephrine auto‑injector is not available, and then call 911 or local medical emergency services. Customers should contact their physician or HCP if they have experienced any problems that may be related to taking or using this drug product.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.
This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

Sanofi US is committed to patient safety and the quality of Auvi‑Q, and will continue to work closely with customers and regulatory authorities to resolve this issue in a timely manner.

Monday, September 7, 2015


The rules regarding volunteers in the school have been updated:
  • If a family member was already a recognized volunteer last year then they will not have to do anything new until July of next year (2016)
  • Beginning in July of 2016 all volunteers will need 2 PA clearances, but PA will pick up the cost.
  • Also beginning in July of 2016 all volunteers who have lived in PA less than 10 years will require a Federal clearance with fingerprinting.
The details can be found in these documents: